Recently rebranded Actylis is stepping up its drug ingredients game.
The raw materials manufacturer—which debuted last fall after chemical supply veteran Aceto wedded its business with 10 other companies—has kicked off operations at a new “innovative” active pharmaceutical ingredient (API) manufacturing facility in Eugene, Oregon. The 30,000-square-foot plant is equipped to crank out APIs and excipients at both clinical and commercial scales, Actylis said in a release.
After starting construction in February 2021, Actylis completed the plant build-out in September 2022 and wrapped up commissioning and qualification work in January of this year. Manufacturing efforts have since begun at the facility, Actylis CEO Gilles Cottier said in a statement.
The plant features seven manufacturing suites equipped with multiple reactors to help meet the needs of a “variety of chemistries,” site director Christine Bellmor added in the release.
As an added perk, the new plant is a quick, 10-minute drive from Actylis’ R&D facility, which should streamline the scaling and development of new processes for the facility, Bellmor said.
Boasting additional sites in Canada, Ireland, India and the U.S., Actylis has a footprint in 10 countries. As of September, Actylis employed more than 850 staffers around the world, Cottier said in an interview last year.
The company emerged last fall by integrating Aceto with 10 recently acquired specialists in manufacturing and sourcing. Upon its debut, Actylis set the goal to carve out a spot as one of the world’s top manufacturers and sourcing experts for raw materials and performance ingredients.
Aceto, for its part, had been in the sourcing and supply game for more than 70 years. The company decided to embark on a business transformation shortly after the arrival of Cottier in 2019.
Aside from its significant stake in the pharmaceutical industry, Actylis also runs in nutritional, agricultural and specialty chemicals markets.